Senores Pharmaceuticals Limited develops and manufactures a range of pharmaceutical products primarily for the regulated markets of the US, Canada, and the UK, while also serving emerging markets.

The company’s product portfolio consists of Amphetamine Sulfate Tablets, Hydroxychloroquine Sulfate Tablets, Ketoconazole Tablets, Butalbital, Acetaminophen and Caffeine Capsules, Mexiletine Hydrochloride Capsules, Ketorolac Tromethamine Tablets, Diclofenac Potassium Tablets, Diclofenac Potassium Tablets, Nicardipine Hydrochloride Capsules, Escitalopram Tablets, Prochlorperazine Maleate Tablets USP, Terazosin Capsules USP, Morphine Sulfate Tablets, Methadone Hydrochloride Tablets, Cyclobenzaprine Hydrochloride Tablets, Irbesartan Tablets, Risperidone Tablets Topiramate Capsules, and Ivermectin Tablets for regulated markets. As of September 30, 2024, the company has launched 55 products in key therapeutic areas, including antibiotics and anti-fungal treatments. They have established partnerships with distributors and hospitals across several states in India.

For the year/period ended (Rs. in Cr.)

For year/ period ended ( in Cr.)

• Ability to  cater  to  the  Regulated  Markets of  US,  Canada  and  the  United  Kingdom through  our  US  FDA  approved formulation manufacturing facility in the US;
• Distinct niche product portfolio built in a short span for Regulated Marketsof US, Canada and the United Kingdom;
• Long-term marketing arrangements with pharmaceutical companies in the Regulated Markets, US, Canada and the United Kingdom;
• Presence in the Emerging Markets with a product portfolio, including specialty or complex products;
• R&D capabilities driving our differentiated portfolio of products;6.Professional management teams for our diverse business verticals

1. Investment in one of the Subsidiaries, Havix Group, Inc. d/b/aAavis Pharmaceuticals(“Havix”), to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in the Atlanta Facility;
2. Repayment/pre-payment, in full or in part, of certain borrowings availed by the Company;
3. Investment in the Subsidiary, namely, Havix, for re-payment/pre-payment in whole or part of certain borrowings availed by such Subsidiary;
4. Funding the working capital requirements of the Company;
5. Investment in the Subsidiaries, namely, Senores Pharmaceuticals Inc. (“SPI”)and Ratnatris Pharmaceutical Private Limited (“Ratnatris”), to fund their working capital requirements.
6. Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.

At the upper band of IPO, the company is valued at 28.68 times P/E multiples. Hence, well-informed investors may subscribe this IPO for medium to long term.